SE9603533D0 - Specific peptides for the treatment of deabetes mellitus - Google Patents

Specific peptides for the treatment of deabetes mellitus

Info

Publication number
SE9603533D0
SE9603533D0 SE9603533A SE9603533A SE9603533D0 SE 9603533 D0 SE9603533 D0 SE 9603533D0 SE 9603533 A SE9603533 A SE 9603533A SE 9603533 A SE9603533 A SE 9603533A SE 9603533 D0 SE9603533 D0 SE 9603533D0
Authority
SE
Sweden
Prior art keywords
peptides
atpase activity
deabetes
mellitus
treatment
Prior art date
Application number
SE9603533A
Other languages
English (en)
Other versions
SE9603533L (sv
SE520392C2 (sv
Inventor
John Wahren
Bo-Lennart Johansson
Hans Joernvall
Original Assignee
Creative Peptides Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab
Priority to SE9603533A priority Critical patent/SE520392C2/sv
Publication of SE9603533D0 publication Critical patent/SE9603533D0/sv
Priority to ES97942119T priority patent/ES2278394T3/es
Priority to PL97332494A priority patent/PL332494A1/xx
Priority to AU43915/97A priority patent/AU741901B2/en
Priority to AT97942119T priority patent/ATE347562T1/de
Priority to HU0000432A priority patent/HUP0000432A3/hu
Priority to BR9711573-8A priority patent/BR9711573A/pt
Priority to NZ335231A priority patent/NZ335231A/xx
Priority to DK97942119T priority patent/DK0938503T3/da
Priority to RU99108434/14A priority patent/RU2206336C2/ru
Priority to JP10515410A priority patent/JP2001500893A/ja
Priority to PCT/GB1997/002627 priority patent/WO1998013384A1/en
Priority to EP97942119A priority patent/EP0938503B1/en
Priority to SK394-99A priority patent/SK39499A3/sk
Priority to US09/269,439 priority patent/US6610649B2/en
Priority to TR1999/00694T priority patent/TR199900694T2/xx
Priority to CZ991085A priority patent/CZ108599A3/cs
Priority to DE69737065T priority patent/DE69737065T2/de
Priority to CA002266416A priority patent/CA2266416C/en
Priority to KR1019990702585A priority patent/KR20000048643A/ko
Priority to IL12914397A priority patent/IL129143A0/xx
Publication of SE9603533L publication Critical patent/SE9603533L/sv
Priority to IS5008A priority patent/IS5008A/is
Priority to NO991483A priority patent/NO991483L/no
Priority to BG103362A priority patent/BG103362A/xx
Publication of SE520392C2 publication Critical patent/SE520392C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
SE9603533A 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus SE520392C2 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
IL12914397A IL129143A0 (en) 1996-09-27 1997-09-26 Insulin c-peptides
EP97942119A EP0938503B1 (en) 1996-09-27 1997-09-26 Insulin c-peptides
US09/269,439 US6610649B2 (en) 1996-09-27 1997-09-26 Insulin C-peptides
AU43915/97A AU741901B2 (en) 1996-09-27 1997-09-26 Insulin C-peptides
AT97942119T ATE347562T1 (de) 1996-09-27 1997-09-26 Insulin c-peptide
HU0000432A HUP0000432A3 (en) 1996-09-27 1997-09-26 Insulin c-peptides
BR9711573-8A BR9711573A (pt) 1996-09-27 1997-09-26 Pepetìdeos c da insulina.
NZ335231A NZ335231A (en) 1996-09-27 1997-09-26 Human fragments of insulin C-peptides of the sequence ELGGGPGAG or EGSLQ that have Na/K ATPase stimulating activity
DK97942119T DK0938503T3 (da) 1996-09-27 1997-09-26 Insulin C-peptider
RU99108434/14A RU2206336C2 (ru) 1996-09-27 1997-09-26 Фрагмент с-пептида человеческого проинсулина
JP10515410A JP2001500893A (ja) 1996-09-27 1997-09-26 インスリンｃ―ペプチド
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides
ES97942119T ES2278394T3 (es) 1996-09-27 1997-09-26 Peptidos c de la insulina.
SK394-99A SK39499A3 (en) 1996-09-27 1997-09-26 Peptide, biomimetic organic compound thereof, pharmaceutical composition containing it and its use
PL97332494A PL332494A1 (en) 1996-09-27 1997-09-26 Peptides of c insulin
TR1999/00694T TR199900694T2 (xx) 1996-09-27 1997-09-26 �nsulin C-peptitleri.
CZ991085A CZ108599A3 (cs) 1996-09-27 1997-09-26 Peptid, který je fragmentem C-peptidu lidského inzulinu
DE69737065T DE69737065T2 (de) 1996-09-27 1997-09-26 Insulin c-peptide
CA002266416A CA2266416C (en) 1996-09-27 1997-09-26 Insulin c-peptides
KR1019990702585A KR20000048643A (ko) 1996-09-27 1997-09-26 인슐린 ｃ-펩티드
IS5008A IS5008A (is) 1996-09-27 1999-03-23 C-peptíð insúlíns
NO991483A NO991483L (no) 1996-09-27 1999-03-26 Insulin C-peptider
BG103362A BG103362A (en) 1996-09-27 1999-04-27 Insulin c-peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus

Publications (3)

Publication Number Publication Date
SE9603533D0 true SE9603533D0 (sv) 1996-09-27
SE9603533L SE9603533L (sv) 1998-03-28
SE520392C2 SE520392C2 (sv) 2003-07-01

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus

Country Status (24)

Country Link
US (1) US6610649B2 (sv)
EP (1) EP0938503B1 (sv)
JP (1) JP2001500893A (sv)
KR (1) KR20000048643A (sv)
AT (1) ATE347562T1 (sv)
AU (1) AU741901B2 (sv)
BG (1) BG103362A (sv)
BR (1) BR9711573A (sv)
CA (1) CA2266416C (sv)
CZ (1) CZ108599A3 (sv)
DE (1) DE69737065T2 (sv)
DK (1) DK0938503T3 (sv)
ES (1) ES2278394T3 (sv)
HU (1) HUP0000432A3 (sv)
IL (1) IL129143A0 (sv)
IS (1) IS5008A (sv)
NO (1) NO991483L (sv)
NZ (1) NZ335231A (sv)
PL (1) PL332494A1 (sv)
RU (1) RU2206336C2 (sv)
SE (1) SE520392C2 (sv)
SK (1) SK39499A3 (sv)
TR (1) TR199900694T2 (sv)
WO (1) WO1998013384A1 (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP5452843B2 (ja) * 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
US7557081B2 (en) * 2004-05-27 2009-07-07 Essential Skincare, Llc Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
EP2054437A2 (en) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334338A2 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
CN103119055A (zh) 2010-05-17 2013-05-22 塞比克斯公司 聚乙二醇化c肽
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
EP3570875B1 (en) 2017-02-06 2022-07-06 Biotempt B.V. Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (sv) * 1972-05-15 1975-06-28
JPS5210872B2 (sv) * 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
CA1176158A (en) 1981-08-27 1984-10-16 Ronald E. Chance Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DE69327239T2 (de) 1992-04-13 2000-05-11 Oklahoma Med Res Found Methoden and reagentien zur diagnose von autoantikörpern
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
WO1996001846A1 (en) 1994-07-08 1996-01-25 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type i diabetes
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU728186B2 (en) 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
IS5008A (is) 1999-03-23
DE69737065T2 (de) 2007-06-28
RU2206336C2 (ru) 2003-06-20
IL129143A0 (en) 2000-02-17
JP2001500893A (ja) 2001-01-23
CZ108599A3 (cs) 1999-08-11
BR9711573A (pt) 2000-01-18
SE9603533L (sv) 1998-03-28
CA2266416A1 (en) 1998-04-02
WO1998013384A1 (en) 1998-04-02
KR20000048643A (ko) 2000-07-25
TR199900694T2 (xx) 1999-06-21
NO991483D0 (no) 1999-03-26
AU741901B2 (en) 2001-12-13
BG103362A (en) 2000-05-31
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
US20020107175A1 (en) 2002-08-08
AU4391597A (en) 1998-04-17
PL332494A1 (en) 1999-09-13
HUP0000432A3 (en) 2000-10-30
ATE347562T1 (de) 2006-12-15
US6610649B2 (en) 2003-08-26
NO991483L (no) 1999-05-18
DK0938503T3 (da) 2007-04-10
ES2278394T3 (es) 2007-08-01
NZ335231A (en) 2000-11-24
SK39499A3 (en) 1999-10-08
HUP0000432A2 (hu) 2000-08-28
EP0938503B1 (en) 2006-12-06
EP0938503A1 (en) 1999-09-01
SE520392C2 (sv) 2003-07-01

Similar Documents

Publication Publication Date Title
SE9603533D0 (sv) Specific peptides for the treatment of deabetes mellitus
ATE251642T1 (de) Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
DE69739662D1 (de) Methode zur behandlung von wundheilung in diabetikern
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
ATE193541T1 (de) Insulinotropes hormon
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
DE69710095T2 (de) Pharmazeutische zubereitung zur behandlung von diabetes
HK1145692A1 (zh) 人血管生成素- 的特異結合劑
IL175362A0 (en) Antibodies that bind interleukin-4 receptor
DE69133484D1 (de) Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie
BR9105783A (pt) Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica
WO1999064598A3 (de) Neue insulinanaloga mit erhöhter zinkbindung
DE50009838D1 (de) Humanes antibiotisches protein
PT88067A (pt) Processo para a purificacao de proteina tecidual pp4 placentaria
FI971427A (sv) Peptider och farmaceutiska kompositioner innehållande dessa
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
EP0967276A3 (en) Anti-tumor agent comprising salmosin
RU93058185A (ru) Фактор роста, композиция, способ модулирования действий фактора, способ лечения, способ доставки соединения, способы анализа
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
ATA103997A (de) Wässerige zusammensetzung zum vorgerben von hautblössen oder nachgerben von leder
DK1340507T3 (da) Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
BR8904924A (pt) Composicao de tratamento de couro,sua utilizacao,processo para tratamento de couros,bem como couro assim tratado
ATE206306T1 (de) Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)
BR9703451A (pt) Composto natural para tratamento de diabete câncer e etc

Legal Events

Date Code Title Description
NUG Patent has lapsed